| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01077154 2009-011299-32 Details | 2021-09-28 Interventional | 3 | 4509 | Denosumab Breast Neoplasm… Breast Cancer | Terminated: Amgen decision following Primary Analysis. Not due to safety reason - | |||
| NCT04371523 Details | 2021-09-27 Interventional | 3 | 0 | Hydroxychloroqu… Coronavirus Inf… Corona Virus In… | Study was not initiated due to evidence becoming available that did not support the use of
hydroxychloroquine in this population, with potential risk of added harm - | |||
| NCT04158349 Details | 2021-09-27 Interventional | 1 | 1 | Oxaliplatin Appendiceal Neo… Carcinoma Peritoneal Neop… Appendiceal Can… Colorectal Canc… Peritoneal Carc… | PI Decision - | |||
| NCT03131206 Details | 2021-09-27 Interventional | 1/2 | 5 | Alectinib Carcinoma, Non-… Lung Neoplasms Thyroid Disease… Thyroid Neoplas… ALK-positive No… RET-positive No… RET-positive Th… | Study closed due to slow accrual and lack of efficacy. - | |||
| NCT01058850 Details | 2021-09-27 Interventional | 1 | 3 | Rindopepimut Brain Neoplasms Brain Stem Neop… Diffuse Intrins… Brain Cancer Brain Stem Tumo… Pontine Tumors | Resources can be better spent on higher enrolling studies - | |||
| NCT00880009 2008-006252-21 Details | 2021-09-27 Interventional | 2 | 16 | Bosutinib Letrozole Breast Neoplasm… Breast Cancer | See termination reason in detailed description. Results are not provided because the study was terminated prior to part 2 due to unfavorable risk benefit ratio of the study treatment. | |||
| NCT04335786 2020-001320-34 Details | 2021-09-24 Interventional | 4 | 23 | Valsartan Acute Lung Inju… COVID-19 Respiratory Dis… Respiratory Dis… Severe Acute Re… Syndrome Acute Respirato… COVID SARS-CoV-2 | Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the
REMAP-CAP trial. - | |||
| NCT03722238 Details | 2021-09-24 Interventional | 3 | 613 | Ibuprofen Pain | Study was terminated on 18NOV2020 after an FDA meeting where it was determined no further
actual use data was needed. There were no safety concerns. This study was terminated early due to recruitment problems and challenges. No safety concerns led to the decision to terminate. | |||
| NCT03161509 Details | 2021-09-24 Interventional | 4 | 2 | Acetaminophen Anticonvulsants Carbamazepine Lamotrigine Phenytoin Valproic Acid Bariatric Surge… | publication of better study - | |||
| NCT03054870 Details | 2021-09-24 Interventional | 3 | 226 | Xenon Lung Structure … | Trial met primary efficacy endpoint target. No additional subjects necessary. Unblinded analysis of imaging efficacy data was to be done at completion of study and all blinded readings. Due to the COVID-19 pandemic impact on enrollment, FDA recommended an unplanned interim analysis be performed using blind read data from 200 subjects. Interim analysis was done by independent 3rd party statistician and reviewed by a Data Efficacy Monitoring Committee (DEMC), which recommended termination of the study based on positive results. Sponsor agreed. | |||
| NCT03906448 Details | 2021-09-23 Interventional | 2 | 1 | Temozolomide Astrocytoma Astrocytoma, Gr… Astrocytoma, Gr… | The study was terminated because the Study Chair/IDE Sponsor and Novocure determined that
conducting this trial was not feasible without CMS approval. This multicenter center study was terminated early by mutual decision between the Study Chair/IDE Sponsor and Novocure; therefore, statistical analysis of the 1 participant in the intervention arm was not done. | |||
| NCT03894007 2018-004457-24 Details | 2021-09-23 Interventional | 2 | 6 | Ado-Trastuzumab… Atezolizumab Carboplatin Cyclophosphamid… Docetaxel Epirubicin Maytansine Pertuzumab Trastuzumab Breast Neoplasm… Early-stage Bre… HER2-positive B… | Security and effect data from another ongoing study. - | |||
| NCT01895829 Details | 2021-09-21 Interventional | 1 | 7 | Ferrosoferric O… Head and Neck N… Head and Neck C… | Study halted prematurely and will not resume - | |||
| NCT00508274 Details | 2021-09-21 Interventional | 3 | 52 | Capecitabine Lapatinib Breast Neoplasm… Neoplasms, Brea… | Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable
due to local regulations in China. Data collection post 1-Jul-2019 was not reportable due to local regulations in China. | |||
| NCT02808247 2016-002093-12 Details | 2021-09-20 Interventional | 2 | 80 | Ifosfamide Nintedanib Sarcoma Sarcoma, Soft T… | Exceed of pre-specified number of failures in the experimental arm - | |||
| NCT01364389 2010-019395-73 Details | 2021-09-17 Interventional | 2 | 16 | Prednisone Giant Cell Arte… Polymyalgia Rhe… Inflammatory Di… | Data did not show that the two biologic treatments impacted PMR disease activity to the same
degree as steroid treatment within a 2-week treatment period. This study was terminated because the data did not show that the two biologic treatments impacted PMR disease activity to the same degree as steroid treatment within a 2-week treatment period. | |||
| NCT04330495 Details | 2021-09-16 Interventional | 4 | 0 | Hydroxychloroqu… COVID-19 COVID 19 Immunomediated … | - Care pressures on the investigator team during the COVID-19 pandemic.
- Subsequent appearance of scientific evidence on the lack of efficacy of hydroxychloroquine
in the treatment or prophylaxis of COVID-19 infection. - | |||
| NCT03880487 Details | 2021-09-16 Interventional | 1 | 26 | Oxycodone Analgesia | The Study was terminated early by sponsor - | |||
| NCT03823378 2018-002306-31 Details | 2021-09-16 Interventional | 2 | 97 | Upadacitinib Arthritis Arthritis, Rheu… Rheumatoid Arth… | Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study
(Study M16-063) did not provide appreciable evidence of differentiated clinical effect to
warrant further long-term continuation. - | |||
| NCT03542110 Details | 2021-09-16 Interventional | 4 | 46 | Alirocumab Atherosclerosis Saphenous Vein … | Withdrawal of medication and funding support by Sponsor - |